Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Seeks Japan Approval of IBS-C Treatment Linaclotide
February 25, 2016
- Mitsubishi Tanabe’s New US Unit to Explore M&A Opportunities in Its Field of Specialty
February 25, 2016
- Takeda, ASKA Announce Deal on Ecard Authorized Generic
February 25, 2016
- Rohto Aims to Enter Field of Regenerative Medicine by 2020, with Initial Focus on Fibrotic Diseases
February 25, 2016
- Kyorin Holdings to Shutter Nagano Plant in September
February 24, 2016
- Kipres AG Certain to Hit Shelves before Rivals as Reimbursement Request Filed
February 24, 2016
- Osteoporosis Drug Romosozumab Delivers Positive PIII Data: Amgen Astellas
February 24, 2016
- AZ Initiates Voluntary Recall of Pulmicort Turbuhaler in Japan
February 24, 2016
- PeptiDream, JCR to Collaborate to Discover Peptide-Drug Conjugates that Pass Through Blood-Brain Barrier
February 24, 2016
- Zosyn Generics Face Labeling Revisions, Shipment Halts over False-Positive Concerns
February 23, 2016
- Shionogi’s Naldemedine Yields Positive PIII Results for Opioid-Induced Constipation
February 23, 2016
- Fuso’s Voluntary Recall Escalated to Order-Based Recall
February 23, 2016
- Israel’s Pluristem in Hunt for Japan Partner to Market Placenta-Based Cell Therapies
February 22, 2016
- Merck Serono Likely to Halt Serophene Sales in Japan, Notification Sent Out to Medical Societies
February 22, 2016
- Sanofi Suffers 6.6% Decline in Japan Revenues
February 22, 2016
- Fuso Voluntarily Recalls Maltose-Lactated Ringer’s Inj. and Replas Injection Due to Mislabeling
February 22, 2016
- Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
February 19, 2016
- Fujifilm Begins US PI Study for Cancer Drug FF-10502
February 19, 2016
- Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
February 19, 2016
- US Merck to Sell Daiichi Sankyo’s Lixiana in 13 European Countries
February 18, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…